Navigation Links
DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
Date:7/30/2008

CUPERTINO, Calif., July 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, August 6, 2008 at 9:00 a.m. EDT (6:00 a.m. PDT).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy(TM), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. Remoxy, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
2. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
3. DURECT to Participate in Morgan Stanley Global Healthcare Conference
4. DURECT Provides Update on CHRONOGESIC(R) Research Program
5. DURECT to Participate in Cowen Annual Healthcare Conference
6. DURECT to Participate in Susquehanna Financial Healthcare Conference
7. DURECT to Present at BIO CEO Investor Conference 2008
8. DURECT to Present at 2007 BIO Investor Forum
9. DURECT to Present at UBS Global Life Sciences Conference
10. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
11. STERIS Corporation Announces Fiscal 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Tampa, Fla (PRWEB) , ... January 17, 2017 , ... ... IT Excellence Award for Innovation of the Year. , Each year, Pink ... has taken an innovative approach to address a specific business problem or opportunity. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... visualize, detect, and eliminate cyber threats in real-time, today announced a strategic partnership ... headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader ... new agreement as part of a long-term extension of their media partnership. The partnership, ... of some of the sport’s premier events exclusively on FloWrestling.com as well as usage ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Market 2016-2020" report to their offering. ... The global artificial pancreas devices system ... 2016-2020. Global Artificial Pancreas Devices System Market 2016-2020, has ... industry experts. The report covers the market landscape and its growth ...
(Date:1/17/2017)... 17, 2017 The interventional radiology products market ... from USD 6.35 billion in 2016, at a CAGR ... of this market are rising incidence of chronic diseases, ... surgeries. The global interventional radiology products market ... On the basis of type, the stents segment is ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
Breaking Medicine Technology: